Immune Checkpoint Inhibitors Market - Trends Forecast Till 2028

Immune Checkpoint Inhibitors Market, By Type (PD-1, PD-L1 Inhibitors, CLTA-4 Inhibitors, Elotuzumab, INCB024360, Indoximod, Lirilumab), Therapeutic Application (Lung Cancer, Melanoma Squamous Cell Carcinoma, Urothelial Carcinoma, Blood Cancer, Others), End Users (Hospitals, Specialty Clinics, Oncology Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

Published Date: September, 2020

Base Year Estimate: 2019

Report ID: D-HC-ICIM-35

Format:  

Number of Pages: 320

Domain: Healthcare

Immune Checkpoint Inhibitors Market – Trends Forecast Till 2028

The global immune checkpoint inhibitors market is anticipated to reach USD 38.5 billion by 2020 growing at a CAGR of 18.7% during the forecasting period, 2020-2028. Immune checkpoint inhibitors are a kind of drug which has been used in immunotherapy that helps in targeting cell surface checkpoint proteins for stimulating the recognition and destruction of cancer cells by the immune system. Factors such as the rising prevalence of cancer and raising awareness of immune checkpoint inhibitors are some of the major drivers for the immune checkpoint inhibitors market

Immune Checkpoint Inhibitors Market – Trends Forecast Till 2028

The global immune checkpoint inhibitors market is segmented into type, therapeutic application, treatment, application, end-user, and geography.

The type segment is segmented into PD-1, PD-L1 Inhibitors, CLTA-4 Inhibitors, Elotuzumab, INCB024360, Indoximod, Lirilumab. PD-1 segment is further segmented into PEMBROLIZUMAB (KEYTRUDA), NIVOLUMAB (OPDIVO), CEMIPLIMAB (LIBTAYO). PD-L1 is segmented into DURVALUMAB (IMFINZI), AVELUMAB (BAVENCIO), and ATEZOLIZUMAB (TECENTRIQ).

Therapeutic Application segment is segmented into Lung Cancer, Melanoma Squamous Cell Carcinoma, Urothelial Carcinoma, Blood Cancer and Others

End Users segment is segmented into Hospitals, Specialty Clinics, Oncology Centers and Others

Distribution Channel segment is segmented into Hospital Pharmacies and Retail Pharmacies

Geographically, the global immune checkpoint inhibitors market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America, and insights are provided for each region and major countries within the regions 

North America region is the largest contributor to the immune checkpoint inhibitors market in the forecast period 2020-2028 and the Asia-Pacific region is expected to grow with the highest CAGR during the forecast period 2020-2028.

Key players in the global immune checkpoint inhibitors market are Bristol-Myers Squibb Company, AstraZeneca PLC., Eli Lilly and Company, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd. Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc. among others

The companies have come up with various promotional activities in from of launch, investment, acquisition, and other, for instance:

  • In 2018, Bristol-Myers Squibb Company has announced the collaboration with the Vedanta Biosciences for evaluating Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor
  • In 2018, Kite, a Gilead Company has announced a collaboration with the Sangamo Therapeutics for modifying the genes through Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology platform to develop autologous and allogeneic next-generation ex vivo cell therapies for different cancers

Hence, tremendous progress has been made over the last decade, and yet a lot more to come in recent years.

Available Customizations

In addition to the market data for the immune checkpoint inhibitors market, Delvens offers client-centric reports and customized according to the company’s specific demand and requirement.

Research Methodology

Secondary Research

This research method involved the usage of extensive secondary sources (such as directories and databases)—Hoovers, Avention, annual reports, investor presentation, a conference like Jefferies conference)—to identify and collect information useful for this study of the immune checkpoint inhibitors market. The purpose of secondary research is to identify and collection of extensive, technical, market-oriented, and commercial studies of the global immune checkpoint inhibitors market. Through secondary research, the market is classified and segmented as per industry trends, developments, regional markets, products, and technological developments. 

Primary Research

The primary sources mainly included several industry experts from the core and related industries and suppliers, manufacturers, distributors, alliances, and organizations related to all segments of this industry’s supply chain. In-depth interviews were conducted with various primary respondents—including key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts—to obtain and verify critical qualitative and quantitative information as well as to assess future prospects. The following figure depicts the market research methodology used in drafting this report on the immune checkpoint inhibitors market.

The primary Respondent breakdown is provided below:

Immune Checkpoint Inhibitors Market – Trends Forecast Till 2028

Market Sizing

Top-down and bottom approaches were used to derive the market estimate and validate the total revenue of the immune checkpoint inhibitors market. This approach has also been used to derive the market for segmentation and sub-segmentation. 

Data Validation

Impact analysis has been conducted for deriving the market size. After collecting the in-depth quantitative and qualitative data we contact the primary respondents in order to gain a 98.8% of confidence level on our data.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants 

Reasons to Acquire

  • Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
  • Gain authentic and granular data access for the immune checkpoint inhibitors market so as to understand the trends and the factors involved in changing market situations
  • Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
  • In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope

 

Report Feature

Descriptions

Market Revenue In 2020

USD 38.5 billion

Growth Rate

CAGR of 18.7% during the forecasting period, 2020-2028

Historical Data

2017-2018

Forecast Years

2020-2028

Base Year 

2019

Units Considered

Revenue in USD billion and CAGR from 2020 to 2028

Report Segmentation

Type, Therapeutic Application, Treatment, Application, End-User and Geography

Report Attribute

Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling

Regional Level Scope

North America, Europe, Asia-Pacific, South America, and the Middle East and Africa

Country Level Scope

U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe)

Companies Profiled

Bristol-Myers Squibb Company, AstraZeneca PLC., Eli Lilly and Company, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd. Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc. among others

Available Customization 

In addition to the market data for the immune checkpoint inhibitors market, Delvens. offers client-centric reports and customized according to the company’s specific demand and requirement.

 

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Choose License Type
Global: 50+ Countries

Note: Report data and information will be by Country.


Regional Report

Note: Report data and information will be by Country.


Country Specific Report

Bundle Reports

50% Discount on all additional reports  

Special Pricing

Avail customised purchase options to meet your specific research requirements.

Custom Tailored Services

Delvens. offers transformed research reports where syndicated reports are not sufficient to provide solutions to your business.

Subscription Model

Get latest and trending updates throughout the year on the reports you buy.